Joe Biden Joins Live All-Star Lineup in L.A. for 'Stand Up to Cancer' Telethon (Exclusive)

Getty

"The vice president will share his personal connection to cancer through his son Beau and discuss the work he's done since he was tasked by the president with leading the Federal White House Cancer Moonshot Task Force," the Office of the Vice President said in a statement.

Vice President Joe Biden is set to touch down in Los Angeles on Friday to take part in the Stand Up to Cancer telethon airing live across several networks Friday night.

Biden's son Joseph "Beau" Biden III died following a battle with brain cancer in May 2015 at age 46.

The fifth biennial telethon, set to broadcast from 8-9 p.m. Friday from Los Angeles, features a roster of A-listers and is aimed at raising money for cancer research. Biden will be in Los Angeles as part of the live telecast.

"The vice president will share his personal connection to cancer through his son Beau and discuss the work he's done since he was tasked by the president with leading the Federal White House Cancer Moonshot Task Force," the Office of the Vice President said in a statement. "Emphasizing that we're at an inflection point in the treatment and prevention of cancer, he'll urge Americans to volunteer their time and energy to fighting cancer through volunteer opportunities on cancer.serve.gov."

Bradley Cooper is executive producing alongside live-event producers Done + Dusted, in collaboration with Stand Up to Cancer's production team.

The fundraiser will air on more than 60 broadcast and cable networks — including the Big Four — and streaming channels in the U.S. and Canada. For the first time, there will be a Spanish version of the Stand Up To Cancer telecast airing nationally on Galavision, HBO Latino, Starz Encore Espanol and Univision Deportes, and locally on Univision Puerto Rico.

It will be broadcast live from the Music Center's Walt Disney Concert Hall in downtown Los Angeles.

More than $370 million has been pledged to support SU2C's model of collaborative cancer research so far.